TY - JOUR
T1 - Aggressive B-cell non-Hodgkin lymphomas
T2 - a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology
AU - Rodriguez-Pinilla, Socorro Maria
AU - Docjinov, Stefan
AU - Dotlic, Snjezana
AU - Gibson, Sarah E.
AU - Hartmann, Sylvia
AU - Klimkowska, Monika
AU - Sabattini, Elena
AU - Tousseyn, Thomas A.
AU - de Jong, Daphne
AU - Hsi, Eric. D.
N1 - Funding Information: Eric D. Hsi is by supported by Eli Lilly, Virtuoso Therapeutics, Novartis, and Abcon. The remaining authors have no financial or non-financial interests that are directly or indirectly related to the work submitted for publication to disclose. Publisher Copyright: © 2023, The Author(s).
PY - 2024/1
Y1 - 2024/1
N2 - Aggressive B-cell non-Hodgkin lymphomas are a heterogeneous group of diseases and our concepts are evolving as we learn more about their clinical, pathologic, molecular genetic features. Session IV of the 2020 EAHP Workshop covered aggressive, predominantly high-grade B-cell lymphomas, many that were difficult to classify. In this manuscript, we summarize the features of the submitted cases and highlight differential diagnostic difficulties. We specifically review issues related to high-grade B-cell lymphomas (HGBCLs) with MYC and BCL2 and/or BCL6 rearrangements including TdT expression in these cases, HGBCL, not otherwise specified, large B-cell lymphomas with IRF4 rearrangement, high-grade/large B-cell lymphomas with 11q aberration, Burkitt lymphoma, and pleomorphic mantle cell lymphoma. Since the workshop, the 5th edition of the WHO Classification for Haematolymphoid Tumours (WHO-HAEM5) and International Consensus Classification (ICC) 2022 were published. We endeavor to use the updated terminology.
AB - Aggressive B-cell non-Hodgkin lymphomas are a heterogeneous group of diseases and our concepts are evolving as we learn more about their clinical, pathologic, molecular genetic features. Session IV of the 2020 EAHP Workshop covered aggressive, predominantly high-grade B-cell lymphomas, many that were difficult to classify. In this manuscript, we summarize the features of the submitted cases and highlight differential diagnostic difficulties. We specifically review issues related to high-grade B-cell lymphomas (HGBCLs) with MYC and BCL2 and/or BCL6 rearrangements including TdT expression in these cases, HGBCL, not otherwise specified, large B-cell lymphomas with IRF4 rearrangement, high-grade/large B-cell lymphomas with 11q aberration, Burkitt lymphoma, and pleomorphic mantle cell lymphoma. Since the workshop, the 5th edition of the WHO Classification for Haematolymphoid Tumours (WHO-HAEM5) and International Consensus Classification (ICC) 2022 were published. We endeavor to use the updated terminology.
KW - Burkitt lymphoma
KW - Diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
KW - High-grade B-cell lymphoma
KW - High-grade B-cell lymphoma/large B-cell lymphoma with 11q aberration
KW - Large B-cell lymphoma with IRF4 rearrangement
UR - http://www.scopus.com/inward/record.url?scp=85166586590&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s00428-023-03579-6
DO - https://doi.org/10.1007/s00428-023-03579-6
M3 - Review article
C2 - 37530792
SN - 0945-6317
VL - 484
SP - 15
EP - 29
JO - Virchows Archiv
JF - Virchows Archiv
IS - 1
ER -